BIOTECH NEWS

Document Sample
BIOTECH NEWS Powered By Docstoc
					              News

    BIOTECH NEWS                                     AstraZeneca invests $100 million in R&D in China
    Joint BIA/ABPI taskforce                         AstraZeneca is to invest           capabilities and is looking this
    on TGN1412                                       $100 million in R&D in China       year to increase the number of
    A joint taskforce has been set up by the         over the next three years,         scientific collaborations with
    BioIndustry Association (BIA) and the            focusing on the benefit and        local Chinese organisations.
    Association of the British Pharmaceutical        value of innovative medicines      AstraZeneca recently signed a
    Industry (ABPI) in the UK to provide             for Chinese patients. The          deal worth $14 million with
    industry input to the expert working group       prime focus of the programme       Wuxi Pharmatech for
    set up to learn from the TGN1412 clinical        will be the establishment of       Compound Collection
    trial adverse events that occurred earlier       the AstraZeneca Innovation         Synthesis and has an existing      AstraZeneca’s Brennan: fully
    this year.                                       Centre China. The company                                             supporting Chinese focus on
                                                                                        collaboration with Shanghai
       The taskforce is co-chaired by Dr David                                                                             innovation.
                                                     has initiated a comprehensive      Jiao Tong University on the
    Chiswell and Sir Colin Dollery, with its
    membership consisting of bioscience and
                                                     search for an appropriate          genetics of schizophrenia.
                                                     location for the Innovation           “With China’s rapid             financial terms and in terms of
    pharmaceutical industry experts in fields
    such as immunology, biopharmaceutical            Centre, which will be              economic growth and                scientific collaboration.
    development and clinical trials. It will offer   operational by the end of          increasing demand for better          “AstraZeneca welcomes and
    input in the areas to be considered by           2009. The Centre will focus        health care, China has             supports the Chinese
    Professor Gordon Duff’s expert group,            on translational science by        become one of the most             government’s continuing policy
    which is reviewing early-stage clinical trial    developing knowledge about         important emerging markets         to recognise investment in
    design with specific reference to biological     Chinese patients, biomarkers       for AstraZeneca and will be        knowledge transfer and R&D
    molecules with novel modes of action;            and genetics. The initial                                             innovation by strengthening IP
                                                                                        important to our future
    new agents with a highly species-specific                                                                              protection, and ensuring timely
                                                     therapeutic area for the           success,” said David Brennan,
    action; and new drugs directed towards
                                                     Innovation Centre will be          CEO of AstraZeneca PLC. “We        market access for Chinese
    immune system targets.
                                                     cancer, which is a major cause     fully support China’s national     patients to innovative
       Aisling Burnand, chief executive of the
    BIA, commented: “As a responsible                of death in China.                 focus on innovation by             products, at prices which
    industry we have brought together this              In addition, AstraZeneca will   substantially increasing our       recognise the value of
    group of world-class individuals with            expand its clinical research       R&D investment, both in            innovation.”
    significant experience in the clinical
    development of innovative medicines. We          Phico Therapeutics and Angel Biotechnology process scale-up contract
    look forward to sharing this expertise with
    Professor Duff and his group to ensure the       Biopharmaceutical contract         Phico’s novel methodology to       development are aimed at
    highest possible standards of patient and        manufacturer Angel                 manufacture Phico’s                Staphylococcus aureus,
    volunteer safety.”                               Biotechnology Holdings plc         therapeutic antibiotic             including MRSA, and
       Dr Richard Barker, director general of        and Phico Therapeutics Ltd, an     products.                          Clostridium difficile. The
    the ABPI added: “Safety is at the forefront      early-stage biotech company          The technology utilises a        developmental programme is
    of all that we do, and it is imperative to       developing a novel anti-           broad-spectrum antibiotic          expected will lead to the GMP
    examine carefully every aspect of the            bacterial platform technology,     protein coupled with a delivery    manufacturing of Phico’s first
    clinical development of ground-breaking          have signed process scale-up                                          product, which is designed to
                                                                                        system that can be
    medicines that work in a novel way related
                                                     and GMP contracts under            programmed to target any           eliminate nasal carriage of
    to that at the centre of this incident. We
    must do everything possible to prevent
                                                     which Angel will evaluate and      selected harmful bacteria.         Staphylococcus aureus,
    such an event ever again occurring               scale up processes utilising       Products currently in              including MRSA.
    without unnecessarily complicating a well-
    established procedure for testing the
    broad range of new medicines.”                   BioFine USA conference
    EU marketing                                     programme nears completion
    authorisation for                                The inaugural BioFine USA           Biotech for Small-Molecule
    biosimilar human growth                          event takes place at the Town       Therapeutics, organised by         BioCatalytics, Inc; Ingenza
    hormone                                          and Country Resort &                avakado Conferences. There         Ltd, Hovione and Excelsyn.
    Cambridge Laboratories has received                                                  are also workshops on Drug         Companies wishing to
                                                     Convention Center, San
    marketing authorisation for the European                                             Metabolism and hERG.               present a paper should
                                                     Diego, USA on September
    Union from the European Medicines
                                                     7-8, 2006. This new                 The programme for the              contact Tom Mulligan on
    Agency’s Committee on Medicinal
    Products for Human Use (CHMP) for its            networking event for                Biotech for Small-Molecule         Tel: +44-1403-220755.
    biosimilar medicinal product, Valtropin®.        companies offering products         Therapeutics conference is         Email: tom@sp2.uk.com
    The product is a recombinant human               and services to the life            almost complete, and                  Attendees can use
    growth hormone for the treatment of              sciences sector features two        includes presentions from          Eventscope software to pre-
    growth deficiency in children, for which         conferences in conjunction          Cylene Pharmaceuticals;            arrange meetings with
    Cambridge Laboratories owns the UK               with the exhibition, and will       TargeGen, Inc; Immusol,            delegates, exhibitors and
    rights. Valtropin was licensed from              attract key executives from         Inc; La Jolla                      visitors attending BioFine
    Biopartners, the private Swiss                                                       Pharmaceutical Company;            USA. For further
                                                     pharma, biopharma and
    biopharmaceuticals company that owns                                                 AndroScience Corporation;          information and FREE
                                                     biotech companies.
    the global rights to the product and is one
                                                     The two conferences are             Merck Research                     visitor registration visit the
    of the first biosimilar products to be
    granted EU marketing authorisation.              MedChem USA, organised by           Laboratories; Pharmatek            website
                                                     Scientific Update, and              Laboratories, Inc;                 www.biofineusa.com



6                             JUNE 2006                                                                                                  www.sp2.uk.com
             DIA is the universally respected forum for quality information exchange
                leading to better medicines that enhance health and well-being.

               Please join your colleagues and learn from the industry’s best
                         at these upcoming DIA meetings in Europe.

 Clinical Statistics for Nonstatisticians Training Course                             Clinical Statistics for Nonstatisticians Training Course
                         June 29-30, ID 06538                                                                October 16-17, ID 06539
        Renaissance Amsterdam Hotel, THE NETHERLANDS                                               Prague Renaissance Hotel, CZECH REPUBLIC


            EudraVigilance Training Course (EV)                                                   US Regulatory Affairs Training Course
   August 23-25, ID 06518       November 8-10, ID 06523                                                      October 23-26, ID 06526
 September 13-15, ID 06519 December 13-15, ID 06525                                           Hotel Crowne Plaza, Amsterdam, THE NETHERLANDS
                  October 4-6, ID 06521
                            EMEA, London, UK
               For local EV training courses, please contact
                                                                                         Pharmacovigilance / Risk Management Conference
                     tatjana.topalovic@diaeurope.org                                                     and Exhibition
                                                                                                              November 2-3, ID 06113
                                                                                                 Hotel Sofitel Paris Forum Rive Gauche, FRANCE
EudraVigilance Medicinal Product Dictionary (EVMPD)
                         Aug 22, ID 06517
                                                                                                   Multi-Track Conference and Exhibition:
                        October 3, ID 06520
                                                                                                   “The Changing World of Clinical Trials”
                       December 12, ID 06524
                            EMEA, London, UK
                                                                                         16th Annual European Clinical Data Management
                                                                                                       European eClinical
                                                                                              European Clinical Research Conference
      European Regulatory Affairs Training Course                                                             November 5-8, ID 06109
                      September 4-5, ID 06503                                                          Congress Centre Basel, SWITZERLAND
        Renaissance Amsterdam Hotel, THE NETHERLANDS
                                                                                           7th Middle East Regulatory Conference (MERC)
 Medical Approach in Diagnosis and Management of                                                            November 14-16, ID 06104
                                                                                               JW Marriott Hotel, Dubai, UNITED ARAB EMIRATES
              ADRs Training Course
                         Sep 26-27, ID 06534
          Hotel Sofitel Paris Forum Rive Gauche, FRANCE                                      European Regulatory Affairs Training Course
                                                                                                            November 27-28, ID 06505
                                                                                                   Renaissance Paris Hotel La Défense, FRANCE
                       Clinical Trial Directive
                    September 28-29, ID 06110
                Scandic Hotel Copenhagen, DENMARK                                                   Pharmacovigilance Training Course
                                                                                                          November 27-Dec 1, ID 06537
                                                                                                   Renaissance Paris Hotel La Défense, FRANCE
                         Pharma Legislation
                    September 28-29, ID 06111
                                                                                                          Cardiac Safety Conference
                Scandic Hotel Copenhagen, DENMARK
                                                                                                              December 4-5, ID 06116
                                                                                                          Maritim Hotel, Berlin, GERMANY
Statistical Methodology in Clinical R&D Conference and
                      Exhibition                                                                Electronic Document Management (EDM)
                        October 4-6, ID 06102                                                                 December 4-5, ID 06114
                Heidelberg Marriott Hotel, GERMANY                                                        Maritim Hotel, Berlin, GERMANY

Practical GCP Compliance Auditing of Trials & Systems
                  Training Course
                        October 4-6, ID 06504
         Hotel Copthorne Tara, London, UNITED KINGDOM


             WORLDWIDE HEADQUARTERS: 800 Enterprise Road, Suite 200, Horsham, PA 19044, USA Tel. +1 215 442 6100 Fax. +1 215 442 6199 dia@diahome.org
          EUROPEAN BRANCH OFFICE: Elisabethenanlage 11, Postfach 4002 Basel, Switzerland Tel. +41 61 225 51 51 Fax. +41 61 225 51 52 diaeurope@diaeurope.org
 DRUG INFORMATION ASSOCIATION LLC: Level 2, Toranomon 10, Mori Building, 1-18-1 Toranomon, Minato-ku, Tokyo 105-0001, Japan Tel. +81 3 5511 1131 Fax. +81 3 5511 0100
                                                                           diajapan@diajapan.org
              News

                                                   Clariant sells Pharmaceutical Fine Chemicals to
    BIOTECH NEWS                                   TowerBrook Capital Partners
    Sigma-Aldrich and Rosetta
                                                   Clariant has announced the          building blocks, regulatory          Main, Germany.
    Inpharmatics establish
                                                   sale of its Pharmaceutical Fine     starting materials,                     Jan Secher, Clariant’s chief
    siRNA design partnership                       Chemicals unit to TowerBrook        intermediates and active             executive, said: “The
    Sigma-Aldrich has entered into an
    exclusive arrangement to access Rosetta        Capital Partners, LP for a          pharmaceutical ingredients           Pharmaceutical Fine
    Inpharmatics’ bioinformatics design tools      transaction value of about          (APIs) for both the innovative       Chemicals business sharpened
    for siRNA research and development             SFr110 million. The company         and the generic                      its strategy and improved its
    purposes. The licence agreement will           said the sale marks a further       pharmaceutical industry. The         efficiency, enabling it to
    provide RNAi researchers with cutting-         step in its strategy to focus its   new autonomous entity will be        become one of the industry’s
    edge siRNA design technology for               portfolio on core activities.       one of the world’s largest           leading suppliers. As an
    enhanced performance through improved          TowerBrook Capital Partners,        businesses based solely on           independent entity supported
    specificity and silencing. Sigma- Aldrich      LP is a private equity firm with    pharmaceutical fine                  by a committed investor, it
    plans to utilise the design technology to
                                                   more than $2.5 billion under        chemicals, with 2005 sales of        has an excellent opportunity
    launch human and model organism siRNA
                                                   management. The firm has            around SFr210 million and            to perform well in the future.
    whole genome libraries, to deliver siRNA
    panels targeted to specific gene families,     offices in London and New           employing about 800 people.          On the Clariant side, this is
    and to provide access to single-target         York and focuses on making          It will operate all                  another important step in
    pre-designed siRNAs through an enhanced        investments in European and         manufacturing sites of Clariant      focusing our business portfolio
    web interface on Sigma-Aldrich’s website.      North American companies.           Pharmaceutical Fine                  on innovative applications
    Researchers will have access to products          The Pharmaceutical Fine          Chemicals and will be                with value-increasing service
    that will be manufactured worldwide by         Chemicals unit manufactures         headquartered in Frankfurt am        components.”
    the Sigma Genosys and Proligo operations.

    Applied Biosystems and                         Activotec
    SAIC-Frederick
    collaborate on cancer                          completes
    biomarkers research
    Applied Biosystems has entered into a
                                                   funding round
    collaboration with the Core Genotyping         UK chemistry and
    Facility, SAIC-Frederick, Inc on a series of   biochemistry services company
    biomarker studies for cancer research. The
                                                   Activotec has completed a
    US National Cancer Institute-funded Core
    Genotyping Facility will use Applied
                                                   major funding round which it
    Biosystems’ entire TaqMan® Drug                says will enable it to
    Metabolism Genotyping Assay collection to      accelerate its growth. The
    examine genetic variations in the HapMap       company has its trading base
    and SNP500Cancer samples in order to           in Cambridge and an R&D and
    validate additional cancer biomarkers.         production facility in              Activotec: new funding for chemistry and biochemistry services.
      In support of the NCI, the Core              Southampton, and was
    Genotyping Facility is using more than         founded in 2002 as a spin-out       peptide and protein synthesis.       development while expanding
    2,400 TaqMan Drug Metabolism                   from the University of              The funding was raised               our current business. This will
    Genotyping Assays to generate the                                                  through a syndicate mainly
                                                   Southampton. Activotec                                                   assist us in our dual strategy of
    genotypes for samples from the
                                                   provides high-technology            composed of private investors.       creating and licensing
    International HapMap Project and from the
    NCI’s SNP500Cancer standard sample             products and services for           Activotec chief executive, Chris     technology to drug developers
    panel. In addition, select assays with         chemistry and biochemistry          Littlewood, commented: “The          while also quickly growing our
    significant correlation from data analysis     applications including a range      funds will be invested in            custom peptide and
    will be used to genotype individuals who       of products and services for        further research and                 synthesiser sales.”
    participated in a pharmacogenetic study at
    the NCI evaluating treatment for non-
    Hodgkin lymphoma.                              EU marketing authorisation for biosimilar human growth hormone
      “The objective of this study is to better     Biopartners has received           co-developed a number of               “We are delighted to have
    understand the genetic differences
                                                    marketing authorisation for        biopharmaceutical products           gained EU marketing
    associated with individual responses to
                                                    the European Union from the        including Valtropin and a            authorisation for Valtropin,”
    cancer treatment,” said Dennis A. Gilbert,
    PhD, chief scientific officer of Applied        European Commission for its        sustained release formulation        said Jean-Noël Treilles, CEO of
    Biosystems. “Because our TaqMan Drug            biosimilar medicinal product       of Valtropin. The company in-        Biopartners. “As the first
    Metabolism Genotyping Assays were               Valtropin, a recombinant           licensed Valtropin from LG           product in our broad and
    developed using extensive computational         human growth hormone used          Life Sciences and has                advanced pipeline to gain
    analysis in combination with assay              for the treatment of human         commercialisation rights for         authorisation, this marks a
    optimisation and validation that identified     growth deficiency in children      the product in Europe, Japan         major milestone for
    novel and well-known gene variants, we          and Turner’s Syndrome. This        and other parts of Asia.             Biopartners.
    believe they represent the most complete        product is only the second         Biopartners is currently               “We aim to make Valtropin
    set of drug metabolism assays available to
                                                    biosimilar to receive EU           developing a sustained release       available to health care
    the scientific research community.”
                                                    marketing authorisation.           version of Valtropin which is        professionals and patients
                                                    Biopartners, jointly with LG       currently in Phase III clinical      through our distributors before
                                                    Life Sciences, has                 trials.                              the end of the year.”


8                           JUNE 2006                                                                                                      www.sp2.uk.com
                                                                                                                           News

Thermo Electron and Fisher Scientific in reverse merger deal                                                    officer of Fisher, will be
                                                                                                                stepping aside in support of
Thermo Electron Corporation       services. Under the terms of                reverse merger with Thermo as     the new management team.
and Fisher Scientific             the agreement, Fisher                       the acquirer.                     He will be concentrating on
International Inc have agreed     shareholders will receive two                  Marijn E. Dekkers, president   launching new business
to combine the two companies      shares of Thermo common                     and chief executive officer of    opportunities and will remain
in a tax-free, stock-for-stock    stock for each share of Fisher              Thermo, will become president     an adviser to the company.
exchange. The new company         common stock they own.                      and chief executive officer of          .
                                                                                                                Jim P Manzi, chairman of the
will be named Thermo Fisher       Upon completion of the                      the combined company, and         board of Thermo, will serve on
Scientific Inc and is expected    transaction, Thermo’s                       Paul M. Meister, vice chairman    the board of directors of the
to have 2007 revenues of          shareholders would own about                of the board for Fisher, will     combined company. Thermo
more than $9 billion. Thermo      39 per cent of the combined                 become chairman of the board      Fisher Scientific’s board of
and Fisher have                   company, and Fisher                         of the combined company.          directors will be comprised of
complementary technology in       shareholders would own                      Following the close of the        eight members, with five
instrumentation, life science     approximately 61 percent. The               transaction, Paul M. Montrone,    nominated by Thermo and
consumables, software and         transaction will be treated as a            chairman and chief executive      three nominated by Fisher.

Sigma-Aldrich
establishes RNAi
Partnership Program to
                                                                                  A World Leader in
advance functional                                                              cGMP Oligonucleotides
genomics
Sigma-Aldrich, a leader in
RNAi and functional
genomics, and a member of
The RNAi Consortium (TRC),
has established a worldwide
RNAi Partnership Program
with select academic
institutions to advance
functional genomics research.
Scientists from participating
organisations will benefit from
access to a broad portfolio of
intellectual property, early
access to emerging new
technologies, and special
partnership pricing on Sigma’s                                               Solid Phase                         Solution Phase
range of functional genomics                                                 Production                            Production
and RNAi products.                                                                                   ec 2006
                                                                                              Chemspa, Swiss
   Researchers at participating                                                                   ev
                                                                                                  Gen
institutions will have early
access to new technologies
that are developed through
Sigma-Aldrich’s collaborations
with TRC, Oxford BioMedica
and Benitec. The partnership
programme will also facilitate                                                    Now Stronger
collaborations with scientists
at Sigma-Aldrich to validate
current and emerging RNAi
                                                                                   Than Ever
technologies.
   Programme participants will
also benefit from a dedicated
support team on Sigma’s                       Girindus AG Headquarters
                                                            Buchenallee 20
functional genomics product                   D-51427 Bensberg (Cologne)

portfolio. This extensive                                        Germany
                                                   Tel: +49 2204 926-900
product offering includes the                          oligo@girindus.com

Lentivirus-based MISSION™                     Girindus Sales Corporation
TRC shRNA libraries, targeting                34650 US Highway 19 North
                                                  Palm Harbor (Tampa Bay)
more than 15,000 human                                 Florida 34684, USA

and mouse genes, activated
                                                     Tel: +1 727 781 8383
                                                       oligo@girindus.com    Solvay Organics
lentiviral particles, custom
siRNA, and qPCR reagents.



www.sp2.uk.com                                                                                                  JUNE 2006                    9
           News

                                               Gene Logic and Organon collaborate on new pharma applications
 EVENTS                                        Gene Logic Inc and Organon         drug candidate both                vice president of global
 (Events organisers’ contact details on
 page 12)                                      have entered into a drug           companies will become equal        research & development at
                                               repositioning agreement to         owners and may decide to           Organon commented: “We
 June 21-23, 2006                              seek alternative development       jointly develop and                believe Gene Logic’s
 APIs EUROPE                                   paths for multiple drug            commercialise the product.         programme has the potential
 Spazio Villa Erba, Como, Italy                candidates for which Organon       Gene Logic will receive a          to find new value in our
 Organiser: CPA                                previously discontinued clinical   success-based milestone            previously deprioritised drug
                                               development. Gene Logic will       payment for each therapeutic       candidates. Organon continues
 June 26-27, 2006                              investigate new therapeutic        candidate that Organon             to seek new technologies to
 Clinical Trials in Cancer
                                               uses for the compounds and         chooses to enter into clinical     increase our drug research
 Holiday Inn Bloomsbury, London, UK
                                               upon discovery of potential        development.                       output. This technology is an
 Organiser: SMi
                                               new therapeutic utility for a         David Nicholson, executive      opportunity to address that.”
 July 17-19, 2006
 Organic Process Research and
 Development                                   Diatos acquires cancer product from                                   payments of up to $4.7
                                                                                                                     million, based on regulatory
 Vancouver, Canada                             Gilead Sciences                                                       approval of new indications,
 Organiser: Scientific Update
                                               Diatos SA, a                       daunorubicin, which has been       and royalties on net sales.
 August 26-27, 2006                            biopharmaceutical company          approved for AIDS/HIV-related      On the basis of data derived
 Microwave-Assisted Organic                    focusing on the research,          Kaposi’s sarcoma and is sold       from DaunoXome’s
 Synthesis                                     development and                    by Gilead in more than 20          commercial use and from
 Budapest, Hungary                             commercialisation of targeted      countries.                         clinical studies in acute
 Organiser: Karl-Franzens University, Graz     anti-cancer therapies, has            DaunoXome has also been         leukemic diseases, Diatos will
 and Eotvos Lorand University, Budapest        formed an exclusive licensing      evaluated in clinical studies      seek approval from European
                                               agreement with Gilead              for potential efficacy and         regulatory authorities for the
 September 7-8, 2006
                                               Sciences, Inc for the              safety in acute myeloid            use of DaunoXome in acute
 BioFine USA
 Town and Country Resort & Convention
                                               worldwide development and          leukemia (AML). It is a widely     leukemia. Diatos intends to
 Center, San Diego, USA                        commercialisation rights to        used chemotherapeutic agent,       continue to market
 Organiser: avakado                            cancer product DaunoXome.          principally in hematological       DaunoXome for treatment of
                                               The product is a marketed          malignancies. Gilead will          Kaposi’s sarcoma in Europe
 September 7-8, 2006                           liposomal formulation of           receive upfront and milestone      and Brazil.
 Biotech for Small-Molecule
 Therapeutics
 Town and Country Resort & Convention
 Center, San Diego, USA
                                               sanofi-aventis and partners in hepatotoxicity project
 Organiser: avakado                            Aureus Pharma and                  development process. Toxicity      toxicological experts to validate
                                               ChemAxon have been awarded         knowledge exists but data is       the products. Software solution
 September 7-8, 2006
                                               a European Eureka project          scattered in numerous sources      provider ChemAxon and
 MedChem USA
 Town and Country Resort & Convention          along with pharmaceutical          and cannot easily be accessed      Budapest University of
 Center, San Diego, USA                        partner sanofi-aventis and         simultaneously. Having access      Technology and Economics,
 Organiser: Scientific Update                  academic partner Budapest          to a knowledge database            which has expertise in
                                               University of Technology and       containing detailed biological     chemical reaction modeling,
 September 17-21, 2006                         Economics to build a new           and chemical data and              will extend their software tools
 Society for Biomolecular                      knowledge base related to          associated analysis                to deal with reactions and
 Sciences Annual Conference and                hepatotoxicity. The KnowTox®       applications will lead to better   substrates involved in the
 Exhibition                                    project is also aimed at           use of available knowledge         metabolism of compounds and
 Washington Convention & Trade Center,                                                                               also develop predictive tools
                                               building a knowledge base of       and time- and cost-saving
 Seattle, Washington, USA
                                               related predictive tools to        during drug development.           for hepatotoxicity. It is
 Organiser: Society for Biomolecular
 Sciences                                      extend the value of the              In the project Aureus            expected that the KnowTox
                                               system.                            Pharma will provide its            Knowledge database and
 October 3-5, 2006                                Drug-induced hepatotoxicity     expertise in building chemical     predictive tools will be
 CPhI Worldwide                                or liver damage/disease is a       biology knowledge databases        commercially available upon
 Paris-Nord Villepinte, Paris, France          major concern during the drug      and sanofi-aventis will provide    completion of the project.
 Organiser: CMP Information

 October 5-6, 2006
                                               Vaccine technology patent for Allergy Therapeutics
 cGMP: Current Good                            Specialist pharmaceutical          countries in Europe. The           anti-infective field, as a
 Manufacturing Practices                       company Allergy Therapeutics       patent covers vaccine therapy      prophylactic or preventative
 The Loews Philadelphia Hotel, Philadelphia,   plc has been granted a broad       for any bacterial or viral         vaccine. The patent also
 USA                                           technology patent for the          disease and uses an antigen        covers the use of this
 Organiser: Cambridge Healthtech Insitute      combination of MPL® with           derived from the target            advanced adjuvant system in
                                               tyrosine and an antigen by the     organism.                          cancer immunotherapy in
                                               European Patent Office.               The technology may              addition to bacterial and viral
                                               The patent covers 24               therefore be employed in the       immunotherapy.
More events on page 12



10                        JUNE 2006                                                                                                www.sp2.uk.com
                                                                                                                           News

Degussa presents chiral chemistry award                                                                   CIA NEWS
                                    Degussa Award for Chirality in     of Heidelberg and received his
                                                                                                          CIA welcomes UK
                                    Chemistry. Established in          PhD from the University of
                                    2004, the Award recognises         Marburg. After post-doctoral
                                                                                                          government momentum on
                                    innovative work in chiral          studies at Harvard University,     energy
                                                                                                          The CIA has welcomed a series of UK
                                    chemistry performed by a           he started his independent
                                                                                                          government announcements recognising
                                    young chemist. Professor Bach      research at the University of      the significance of security of energy
                                    has contributed widely to the      Münster in 1992. He became         supply and related price concerns in the
                                    chemistry of chiral molecules      Professor of Chemistry at the      country. Support from the Prime Minister,
                                    and has pioneered several new      University of Marburg in 1997      Tony Blair, for the renewal of the UK’s
                                    synthetic methods. The             and moved to his present           nuclear generation capacity was especially
                                    international jury, who together   position at the Technical          welcomed; in an earlier announcement,
                                    with Degussa scientists            University of Munich in 2000.      the Secretary of State for Trade and
                                    decided the recipient of the       The award has a value of           Industry, Alistair Darling, appealed to
                                                                                                          planning authorities to be more mindful of
                                    award, recognised the work he      €5,000 and was presented to
                                                                                                          the urgent national interest when
                                    has done in the use of chiral      Professor Bach at the Modern
                                                                                                          considering applications for new gas
Professor Thorsten Bach: receives   catalysts, particularly in         Synthetic Methods and Chiral       storage facilities. He also announced the
Degussa’s chiral chemistry award.   photochemical reactions. His       Europe 2006 conference             creation of a Business Energy Forum to
                                    work has led to new routes to      organised by Scientific Update     address urgent concerns for the next
Professor Thorsten Bach of the      molecules that are of interest     and this year sponsored by         winter.
Technical University of Munich      to pharmaceutical companies.       Degussa Exclusive Synthesis &         Stephen Elliott, Chief Executive at the
is this year’s recipient of the     Bach studied at the University     Catalysts.                         CIA, commented:
                                                                                                             “Secure, competitively priced energy
                                                                                                          supplies are vital to the future of chemical
MorphoSys and Schering-Plough in R&D agreement                                                            manufacturing in this country and we see
                                                                                                          nuclear energy as an essential component
MorphoSys AG has signed an          Schering-Plough with the           Schering-Plough Biopharma.         of a diversified, low-carbon energy supply
initial two-year licence            option to develop HuCAL-           “The agreement signed today        mix for the long term future.”
agreement with                      derived therapeutic antibodies     is our twelfth with a top 20          Turning to the more immediate issue of
Schering-Plough Corporation         against up to ten disease-         pharmaceutical company,”           gas storage he added:
for the use of MorphoSys’s          related targets. During the        commented Dr Simon                    “As the UK’s natural resources decline
                                                                                                          we are becoming more reliant on other
HuCAL GOLD® technology in           initial two-year term of the       Moroney, chief executive
                                                                                                          sources of gas to meet our national needs.
the research and development        agreement, which also              officer of MorphoSys. “This
                                                                                                          The CIA welcomes the considerable
of human therapeutic                provides Schering-Plough with      deal marks further progress in     investment being undertaken to enable
antibodies. MorphoSys has           the option of an extension of      the successful execution of our    new supplies to reach our shores.
granted access to its               up to three more years,            strategy to strengthen the         However, last winter taught us that this
proprietary antibody library to     MorphoSys’s HuCAL GOLD®            pipeline of therapeutic            import capacity is not always fully utilised.
Schering-Plough for use in its      antibody library will be           antibodies based on our            It is therefore essential that the UK rapidly
drug discovery programmes at        installed at Schering-Plough’s     proprietary technology through     increases its gas storage capabilities to
one research site. The              research site in Palo Alto,        strategic deals with quality       ensure all demand, both domestic and
contract also provides              California, the location of        partners.”                         industrial, can be met even when import
                                                                                                          flows to the UK are restricted.”
                                                                                                             The CIA has also welcomed the decision
                                                                                                          by the electricity and gas markets
Optima Procurement Solutions launches                                  that will have on-line access      regulator Ofgem to implement
                                                                       to individual project
on-line pharma outsourcing service                                     descriptions offered for tender,
                                                                                                          energywatch’s network code modification
                                                                                                          to release close to near real time flow
Optima Procurement Solutions        efficiency and cost-savings in     thereby opening up a project       information.
has launched its OptimaCRO          securing their outsourcing         to only a handful of CROs, or         The CIA said it agreed with Ofgem that a
on-line resource for the            needs. Companies will have         potentially to the entire global   central foundation of any competitive
pharmaceutical, fine chemical       free access to information         CRO community. We can              market is information provision, and that
and biotechnology industries,       provided by contract research      protect the identity of our        the implementation of this modification
designed as a single point of       organisations (CROs),              biopharma client, so that bids     represented an important development in
                                                                                                          the UK market.
reference for                       identifying those that can best    received for projects will be
                                                                                                             Alan Eastwood, Head of Competitiveness
biopharmaceutical outsourcing       serve their needs in Europe,       blind and therefore an open        and Utilities at the CIA, said:
on a global scale.                  the Americas or Asia.              and fair reflection of the            “We recognise the leading role the UK,
   The dedicated and secure            Dr Steve Allin, outsourcing     current market. Alternatively,     Ofgem and North Sea producers have
portal enables worldwide            advisor to OPS, and a founder      rather than an acting as a         taken within Europe in data provision and
procurement of services for         of UK-based research services      global marketplace, we can         we believe that this modification
the industry.                       company Charnwood                  customise our unique software      represents an important step for the UK
   Biopharmaceutical clients        Molecular Ltd, commented:          to form a bespoke, in-house        along the road to transparency. We now
can control either global              “With OptimaCRO, our            system for individual              look to Ofgem to ensure that the light is
‘sealed bid’ events, or a           biopharma partners can             companies, should that be          turned on in Europe.”
reverse auction system, and         develop their own unique list      preferred.”
can drastically improve             of preferred CRO suppliers            See www.optimacro.com



www.sp2.uk.com                                                                                            JUNE 2006                                 11
           News

                                          Merck & Co to acquire GlycoFi                                         of 2006, subject to customary
EVENTS                                    Merck & Co, Inc is to acquire      speed, cost and quality over
                                                                                                                closing conditions and
                                                                                                                clearance under the Hart-
November 16-17, 2006
NanoBiotech World Congress                GlycoFi, Inc, a biotechnology      current methods of producing       Scott-Rodino Anti-Trust
Boston, USA                               company specialising in yeast      monoclonal antibodies and          Improvements Act.
Organiser: Select Conferences             glycoengineering and               other protein therapeutic          GlycoFi, which was founded in
                                          optimisation of biologic drug      agents.                            2000, is based in Lebanon,
December 1-3, 2006                        molecules. Glycoengineering           Merck will acquire 100 per      New Hampshire, USA and has
CPhI India                                provides the ability to make       cent of the equity of GlycoFi,     about 55 employees. Merck
Bombay Exhibition Centre                  proteins such as monoclonal        which will become a wholly-        and GlycoFi have been
Organiser: CMP information                antibodies with pre-specified      owned subsidiary of Merck &        partners since late 2005,
                                          and defined human                  Co, Inc. The all-cash              when they established a
                                          carbohydrate side chains. The      transaction is valued at about     strategic alliance and research
Organisers’ contact details               ability to make such proteins      $400 million and is expected       collaboration to develop novel
                                          in yeast has advantages of         to close in the second quarter     biologic candidates.
avakado
Contact: Mark Harrington or Jaymin Amin
Tel: +44 1403 220760
                                          Designer microorganisms for
Email: mark@sp2.uk.com or
jaymin@sp2.uk.com
                                          steroid drug production
Web: www.biofine.uk.com                                                      methods, a microbial               development of customised
                                                                             production strain will be          microorganisms hallmarks the
Cambridge Healthtech Institute                                               optimised to reduce the            growing importance of white
Contact: Margit Eder                                                         amount of side products and        biotechnology for efficient
Tel: +1 617 630 1378                                                         to increase the amount of the      production processes,”
Email: eder@healthtech.com                                                   desired steroid intermediate.      commented Dr Jürgen Eck,
Web:                                                                         The goal is the optimised          head of research at BRAIN AG.
www.healthtech.com/2006/gmp/index.asp                                        fermentation of steroid drugs      “With our molecular biology
                                                                             using improved production          technology platform we can
CMP Information
                                          Biotechnology company              strains fed with plant raw         selectively modify and improve
Tel: +31 346 559444
Fax: +31 346 573811                       BRAIN AG and Berlin,               materials. Optimised microbial     the genomes of established
Web: www.cphi.com                         Germany based                      biotransformation processes        production strains in order to
                                          pharmaceutical corporation         are expected to increase           exclude yield-limiting genes.
CPA                                       Schering AG have established       product yields and to              Through the use of these
Tel: +39 02 67380474                      an agreement to co-operate on      supersede time-consuming           ‘designer bugs’ more efficient
Fax: +39 02 6692373                       the improvement of a               and complex product                transformations of steroidal
Email: info@apiseurope.com                production process for steroid     processing.                        intermediates willl be
Web: www.apiseurope.com                   drugs. Using molecular biology        “The identification and         achieved”.
Karl-Franzens University
Contact: Prof. C. Oliver Kappe            Cyprotex launches in vitro ADME data guide                            provide a resource for
Tel: +43 316 3805352                                                                                            scientists who may be
Fax: +43 316 3809840                      Cyprotex has launched an           methods, useful tips and           unfamiliar with commonly
Email: oliver.kappe@uni-graz.at           educational guide to the           frequently asked questions, all    used in vitro ADME assays
Web: www.maos.net                         interpretation of in vitro ADME    of which aim to help               and how best to use the data
                                          data, Everything You Needed        researchers obtain full value      obtained from such assays. At
Scientific Update
                                          to Know About ADME, But            from their ADME and                Cyprotex, we believe in
Contact: Claire Francis
                                          Were Too Afraid to Ask. The        pharmacokinetic data.              sharing our knowledge and
Tel: +44 1435 873062
Email: claire@scientificupdate.co.uk      guide is an on-line instructive    Attached to each ADME assay        expertise with our clients so
Web: www.scientificupdate.co.uk           tool that has been developed       featured within the guide is a     that they are better able to
                                          to assist drug discovery teams     reading list to provide the user   make informed decisions and
Select Conferences                        in selecting compounds for the     with a further source of           we hope this guide will aid
Contact: Paul Raggett                     later stages of the discovery      valuable information.              researchers when selecting
Tel: +44 1787 315117                      process.                              Dr Darwin Cheney,               potential drug candidates.”
Email:                                       Constructed using an easy-      Cyprotex’s chief scientific          To access the guide, visit:
paul.raggett@selectbiosciences.com        to-follow handbook format, the                                        www.cyprotex.com/products/
                                                                             officer, commented: “The
                                          guide includes commonly used       intention of the guide is to       publications_library.htm
SMi Conferences
www.smi-online.co.uk/events
                                          HaptoGuard and University of Calgary in licence agreement
Society for Biomolecular                  HaptoGuard, Inc has signed a       Thomas G. Back, PhD,               manufacture and market
Sciences                                  worldwide exclusive licence        Professor of Chemistry,            products from a library of
Contact: Marietta Manoni                  agreement with UTI Limited         University of Calgary. This        compounds characterised as
Tel: +1 203 743 1336                      Partnership, the University of     new class of compounds has         glutathione peroxidase
Fax: +1 203 748 7557                      Calgary’s technology transfer      the potential to treat patients    mimetics. The company will
Email: mmanoni@sbsonline.org              and commercialisation center,      with cardiovascular disease.       be responsible for worldwide
                                          to acquire rights to a family of   HaptoGuard obtains exclusive       product development
                                          compounds developed by             worldwide rights to develop,       programmes.


12                      JUNE 2006                                                                                            www.sp2.uk.com
                                                 Smart, Reliable
                                                 Purification
                                                 Workhorse
                                                 ... the latest in FLASH
                                                 technology from
                                                 the experts in flash
                                                 chromatography
                                                 Get 4x the power with the new Swedish-engineered
                                                 Biotage SP4 system. Operating at pressures up to 100
                                                 psi, this system is the fastest automated flash
                                                 chromatography system on the market. Purify sample
                                                 loads from milligrams (FLASH 12+, 4.5 g silica) to tens
                                                 of grams (FLASH 75™, 800g silica) using only one
                                                 system. New Touch Logic Control™ is a touch screen
                                                 interface with custom designed intuitive software that
                                                 offers unique features such as TLC-to-gradient and
                                                 Auto-continue sample protection. Expanded fraction
                                                 capacity collects up to 5.8 L with a minimum of 24
                                                 fractions per run. Visit Biotage at Hall A1, Stand 425
                                                 Analytica or Stand B1 Biofine, Barcelona for more
                                                 information.




NEW V-10 Evaporator
Vortex and vacuum evaporation system
Quickly and safely dry dissolved compounds
  • Unique 3-way drying (40x faster)
  • No risk of compound bumping or overheating
  • No sample transfer or reformatting issues
   drys directly into the vial
  • Compatible with liquid handling robots and
    HPLC sample loops
                                                   www.biotage.com
  • Compact footprint
           News

                                               Biacore launches Chinese operation                                       initial job of establishing
 SOCMA NEWS                                    Biacore International AB has         applications support and
                                                                                                                        Biacore’s Chinese business.
                                                                                                                        We believe that China has the
                                               formally launched its own            service of Biacore’s systems in     potential to become a major
 Performance Track - EPA                       operation in China, and is           China. In the outlying areas of     market for our products and
 to increase incentives                        taking over full business            the country Biacore will be         having our own organisation
 The US EPA has published a notice and
                                               responsibility for its products in   supported by a network of           will be crucial in achieving our
 request for comment on actions by the
                                               China. The company said the          local dealers and distributors.     medium-term sales targets.
 agency to increase incentives for
 Performance Track facilities. The actions     new organisation is designed         The organisation will target        Given the broad range of
 being taken by the EPA are in response        to take Biacore’s business to        customers in the life science       customers and applications
 to a report that provided it with             the next stage of its                research, pharmaceutical and        that our systems address, it is
 recommendations on how to enhance             development in the rapidly           biotechnology and food              crucial that we are in a
 incentives to participate. Three              growing market for life science      sectors.                            position to market their key
 workgroups formed by the EPA and the          instrumentation in China.              Erik Walldén, Biacore’s           benefits directly to the
 Environmental Council of States (ECOS)           The Chinese operation will        president and CEO                   customers that we target.
 provided recommendations on                   be headed by Peter Lee, the          commented:                          Given his previous success
 incentives, integration of the
                                               former regional sales manager          “I am pleased to announce         with Biacore’s products in
 performance-based programmes into
                                               for GE Healthcare in Southern        this important strategic            China I am sure that Peter Lee
 the EPA and state budget planning, and
 outreach and recruiting for the               China. He will lead a team of        development for Biacore, and        and his team will be able to
 programme. The incentives include             six people based in Shanghai         at the same time I would like       quickly build a much larger
 expedited permitting on the state and         which will be responsible for        to thank GE Healthcare, our         business for us in this key
 federal level, enhanced recognition, and      the sales, marketing,                previous distributor, for a good    strategic market.”
 simplifying existing flexibility to make it
 more accessible to P-Track facilities.
                                               Evotec and Roche extend medicinal chemistry agreements
                                               Evotec AG has completed two          signed in October 2003 for an       compounds for lead-finding
 Compliance Conference                         service contracts with Roche,        additional two years.               and optimisation programmes.
 for Pharmaceutical                            one extending the global             In the global medicinal             In the medicinal chemistry
 Ingredient Suppliers                          medicinal chemistry                  chemistry agreement a               oncology collaboration, both
 SOCMA’s cGMP Compliance Conference            agreement signed in May              dedicated team of chemists          companies aim to identify and
 for Pharmaceutical Ingredient Suppliers       2004 for a further 12 months         from Evotec supports all of         develop a clinical lead
 takes place from at the Four Points
                                               and the other extending the          Roche’s European and US             candidate for a priority target
 Sheraton Hotel in Washington, DC from
                                               medicinal chemistry                  research sites in the design        within Roche’s oncology
 October 4-5, 2006. The cGMP
 compliance conference is intended for         collaboration in oncology            and synthesis of high-quality       research.
 compliance and regulatory managers of
 active pharmaceutical ingredients
 (APIs), intermediates and excipients          Rentschler and Maxygen in second manufacturing agreement
 manufacturers with job responsibilities       Rentschler Biotechnologie            process and manufacture the         the USA and Europe for the
 covering areas such as quality systems        GmbH has signed a contract           drug to supply the clinical         treatment of hemophilia.
 management, regulatory affairs and            with Maxygen Holdings Ltd for        studies. Additionally, Maxygen      Maxygen’s novel protein will
 plant operations.                             the manufacture of a novel           and Roche have an option to         be evaluated for its
   Programme features include the              factor VIIa protein therapeutic.     retain Rentschler as contract       therapeutic potential in new
 Fundamentals of cGMP Workshop; ICH
                                               The announcement follows a           manufacturer for late-stage         indications such as severe
 Q7a regulatory and legal review; the
                                               recent agreement between             clinical and commercial             bleeding in trauma and
 pharmaceutical ingredient suppliers
 industry colloquium; and the networking       Maxygen and Roche to co-             supplies. Factor VIIa is a          intracerebral haemorrhage
 reception. There will also be a keynote       develop and commercialise the        natural protein with a pivotal      (ICH). Analysts estimate that
 address from an FDA representative.           protein for multiple clinical        role in blood coagulation and       world wide sales of all factor
 For more information contact Lynne            indications. In the first phase      clotting. A recombinant factor      VII products could exceed
 Jones Bashton, email:                         Rentschler will set up the GMP       VIIa product is approved in         $2 billion by 2012.
 jonesl@socma.com or Liz Egitto, email:
 egittoe@socma.com
                                               KNF Flodos pumps for scale-up of processes
 85th SOCMA Annual                             Process chemists at                  heads. Both Stepdos pumps
 Dinner                                        AstraZeneca in Sweden are            are RS-232 compliant, and
 SOCMA’s 85th Annual Dinner will take          using the Stepdos® and               allow the use of software in
 place at the Marriott New York Marquis        Liquiport® ranges of liquid          automated experiments.
 Hotel, New York City on December 11,          pumps from KNF Flodos for            Liquiport pumps are used as
 2006. The Annual Dinner attracts more         the development of their             transfer pumps between larger
 than 600 members and the event                manufacturing processes. The         reactors of 1 litre to 10 litres.
 features entertainment by a well-known        pumps allow good control of          They have Teflon or
 comedian or other artist. For more            very exothermic reactions. The       fluorinated plastic pump
 information contact malene Ward,
                                               Stepdos range offers medium          heads, so are chemically inert.
 email: wardm@socma.com
                                               size pumps of 30 or 80               For further information visit
                                               ml/minute, made with Teflon          www.knf-flodos.ch



14                        JUNE 2006                                                                                                   www.sp2.uk.com
                                                                                                                                                             News

                                                                                                                                             Rapid equilibrium dialysis
Pharmacopeia and Cephalon in therapeutics alliance                                                                                           from Perbio Science
Pharmacopeia has formed a                     therapeutic areas. Cephalon                    Cephalon will provide further
drug discovery, development                                                                                                                  Perbio Science has introduced
                                              will be responsible for                        biology support as required.
and commercialisation alliance                                                                                                               the RED Rapid Equilibrium
                                              identifying promising                          Upon nomination, if any, of
with Cephalon, Inc. The                                                                                                                      Dialysis Device from Pierce.
                                              compounds. The companies                       clinical candidates, Cephalon
primary objective of the                                                                                                                     This new dialysis method in
                                              will work collaboratively to                   will be primarily responsible
alliance is to identify active                                                                                                               plasma protein binding
                                              advance the lead compounds                     for their development and
molecules and bring them                                                                                                                     determination is automation-
                                              to clinical candidates.                        commercialisation.
forward to clinical proof of                                                                                                                 friendly and is used for the
                                              Pharmacopeia will be                           Pharmacopeia retains an
concept, yielding novel                                                                                                                      analysis of multiple drug
                                              principally responsible for                    option to develop candidates
candidates for drug                                                                                                                          candidates.The device has a
                                              medicinal chemistry and                        from the collaboration, subject
development in various                                                                                                                       high membrane surface-to-
                                              primary biology, while                         to Cephalon’s agreement.
                                                                                                                                             volume ratio, reducing dialysis
Vectura and Unilever Ventures spin out speciality pharma company                                                                             time. With short incubation
                                                                                                                                             times, the dialysis device
Vectura Group plc and                         enabling technologies from                     licensed to PharmaKodex two                     inserts are pre-assembled,
Unilever Ventures Ltd have                    Vectura and Unilever. With its                 enabling technologies for use                   disposable and leak-proof. The
jointly established a new                     concentration on pulmonary                     in pharmaceutical products.                     96-well plate format is
speciality pharmaceutical                     technologies, Vectura                          PharmaKodex is developing a                     compatible with automated
company, PharmaKodex Ltd,                     transferred its oral and dermal                pipeline of improved medicinal                  handlers and the individual
to develop a pipeline of                      technologies to a wholly-                      products, focusing on                           insert format also allows for
pharmaceutical prescription                   owned Vectura subsidiary,                      re-purposing existing drugs for                 partial plate use. A reusable
and consumer health products                  PharmaKodex Ltd, in 2005.                      new indications or                              Teflon base plate eliminates
utilising a range of proprietary              In addition, the Unilever                      combinations, or to provide                     non-specific binding . Further
oral and transdermal and                      Group companies have                           improved administration.                        information www.perbio.com



PEOPLE ON THE MOVE
                                                 McLellan worked on the creation of          Serono into a global biotechnology leader,      services worldwide. He has a BSc in Biology
                                               Avecia, including the original financing of   and Europe’s largest biotechnology              from the University of Stirling and an MPhil
                                               the launch, and was appointed group           company, with a market capitalisation of        in Cardiovascular Pharmacology from the
                                               controller on Avecia’s formation in mid-      over $10 billion and worldwide revenues of      University of Wales College of Medicine.
                                               1999. He was previously financial             about $2.6 billion in the year 2005.               Oliff will be responsible for leading
                                               controller of Zeneca Specialties. He joined                                                   business development activities in Europe.
                                               the Pharmaceutical Division of ICI as a       Elizabeth (Betty) Dragon, PhD has joined        He has more than 20 years’ extensive
                                               management accountant in 1983. He             Sequenom as senior vice president of            experience in the medical, diagnostic,
                                               qualified as a Chartered Accountant in        research and development. Dr Dragon has         pharmaceutical, contract research and
                                               1981, after gaining an Economics BA at        over 25 years of diagnostics R&D,               manufacturing industries. Most recently, he
                                               Sheffield University.                         management, and leadership experience,          was European account manager for
                                                 Dr Cox has been president of the            including product development and               Biotechnology Services at Covance
                                               Avecia Biologics business unit since          commercialisation planning and execution        Laboratories Ltd and prior to that gained
  Kevin Cox                                    October 2005. Formerly Avecia’s vice          achievements during her tenure at Roche         industry expertise at Excell Biotech Ltd and
                                               president, biotechnology, he held a series    Molecular Systems from 1990 to 2006. Her        Q-One Biotech Ltd. He has a Degree in
 Reflecting a new phase in its corporate       of senior positions in Avecia’s               most recent role at Roche was as senior         Biomedical Sciences from Glasgow
 development, biotechnology company            predecessors Zeneca Specialties and ICI,      vice president of global standardization        Caledonian University.
 Avecia has announced a new three-man          including periods in Japan and the USA.       and vice president of diagnostics
 Board for its parent, Avecia Holdings plc.    He has over 10 years’ experience in the       development. She earned her PhD in              AGI Therapeutics plc has appointed David
 The new Board members are chief               biotechnology industry, leading Avecia’s      Virology and Cell Biology from Albert           Young, PharmD, PhD, as president of US
 executive officer & director Adrian           biotechnology-based businesses from           Einstein College of Medicine of Yeshiva         operations and executive member of the
 Buckmaster, chief financial officer           their early stages of development through     University.                                     Board of AGI. Dr Young, 53, joins AGI from
 Duncan McLellan and executive director        the subsequent period of high growth. He                                                      the GloboMax Division of ICON plc where he
 Dr Kevin Cox. Buckmaster joined Avecia        chairs the advisory committee of BioNow,      Biopharmaceutical contract manufacturer         was executive vice president with
 in October 2005, having previously been       a health care cluster initiative in the       Angel Biotechnology Holdings plc has            responsibility for strategic drug development
 CEO of the Automotive Products Group and      North-West of England. He has a               appointed two new business development          efforts in the USA. Founded by Dr Young in
 Dobson Park Industries. Earlier in his        Chemistry Degree from Sheffield               managers, Ian Hallett and Gary Oliff.           1997, GloboMax was acquired in 2003 by
 career he was a director of the Dowty         University and a DPhil from Oxford.           Hallett will be responsible for continuing to   ICON plc, a global provider of outsourced
 Group responsible for its Mining Machinery                                                  build Angel’s North American customer           development services to the
 and Polymers Engineering businesses,          Astex Therapeutics recently announced         base. He brings with him more than 20           pharmaceutical, biotechnology and medical
 before leading a buyout of the Mining         the appointment of Leon Bushara as its        years’ experience in research and business      device industries.
 Machinery business in 1989. Much of his       new chief executive officer. He joins Astex   development within the pharmaceutical             Prior to forming GloboMax, Dr Young was
 experience has been in project-based          from Serono SA, where he is currently         and contract research industries, most          with the University of Maryland at Baltimore
 businesses providing bespoke solutions to     senior executive vice president of            recently with Cambrex Biosciences. Prior to     for 11 years where he was a tenured
 customers’ requirements. An engineer by       corporate and business development and        that, he worked at Quintiles where he was       associate professor in the Department of
 training, he studied at Cambridge             a member of the Executive Management          responsible for business development of         Pharmaceutical Sciences and the managing
 University.                                   Board that has overseen the growth of         the preclinical pharmacology and toxicology     director of the Clinical Research Unit.




www.sp2.uk.com                                                                                                                               JUNE 2006                                15

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:31
posted:8/1/2011
language:English
pages:10